Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The combination of oxaliplatin and gemcitabine has proven activity in advanced non-small cell lung cancer (NSCLC). Due to its favorable toxicity profile, this combination is optimal for adding new agents. Bevacizumab is an anti-VEGF monoclonal antibody that has also shown favorable results in advanced NSCLC. This study will add bevacizumab to oxaliplatin and gemcitabine as first line treatment in patients with Stage IIIB and IV NSCLC.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mt. Sinai Medical Center, Miami
• Collaborators: Genentech, Inc.; Sanofi-Synthelabo
• Treatments: Bevacizumab; Gemcitabine; Oxaliplatin

Criteria

Inclusion Criteria:

• Confirmed non-small cell lung cancer, EXCEPT squamous cell cancer

• Stage IIIB or IV disease

• ECOG PS 0-1

• No prior treatment

• No brain metastases

• Must have measurable disease

Exclusion Criteria:

• Deep vein thromboses or pulmonary embolus within 1 year

• History of gross hemoptysis